Filing Flows › Cytokinetics (CYTK) › Guidance & outlook

Cytokinetics (CYTK) guidance and outlook

Cytokinetics (CYTK) raised its guidance on Nov 4, 2026: Stock-based compensation $130M–$140M for FY2026. Cytokinetics' 10-Q filed Nov 4, 2026 makes 39 forward-looking statements.

Guidance and outlook

Latest guidance

From the earnings release filed Nov 4, 2026 (8-K on EDGAR).

Forward-looking statements, 10-Q filed Nov 4, 2026

• We intend to leverage our experience in muscle contractility to expand our current pipeline and expect to identify additional potential drug candidates that may be suitable for clinical development and commercialization.
• Our market research supports our belief that MYQORZO will be highly competitive amongst cardiac myosin inhibitors, potentially eventually achieving a greater than 50% market share in the United States but also growing the cardiac myosin inhibitor category overall.
• At the same time, the National Institute for Health and Care Excellence (NICE) issued guidance recommending aficamten as an option to treat symptomatic oHCM in eligible adults with NYHA class II-III in England and Wales, as an add-on to individually optimized standard care (including beta-blockers, non-dihydropyridine calcium-channel blockers or disopyramide) or alone if those treatments are contraindicated,…
• We expect the UK product launch later this year.
• Based on these results, we plan to submit a supplemental NDA to the FDA for aficamten for the treatment of adult patients with symptomatic nHCM in the fourth quarter of 2026.
• In addition, omecamtiv mecarbil is our late-stage clinical program directed to the hypothesis that activators of cardiac myosin may target the underlying deficit of cardiac contractility in heart failure with severely reduced ejection fraction and address certain adverse properties of existing positive inotropic agents.
• Based on the positive results from ACACIA-HCM, we plan to submit a supplemental NDA to the FDA for aficamten for the treatment of adult patients with symptomatic nHCM in the fourth quarter of 2026.
• AMBER-HFpEF is currently enrolling patients, and we expect to complete enrollment in cohort 1 of the study by the end of 2026.
• Our clinical development program for CK-089 was subject to a partial clinical hold from FDA that limited our ability to dose patients at doses anticipated to result in plasma exposures higher than certain levels.
• We expect that research and development expenses will be flat to declining in 2026 relative to 2025 due to the completion of MAPLE-HCM and ACACIA-HCM, partially offset by the continuation of COMET-HF, AMBER-HFpEF, CEDAR-HCM, FOREST-HCM and any additional clinical trials we may choose to undertake in connection with CK-089 or any other drug candidates.
• We expect selling, general and administrative expenses to increase significantly in 2026.
• With the approval of MYQORZO in the United States, we expect to incur additional expenses for commercial activities, including, but not limited to, the full year impact of the U.S. sales force, training and education, the implementation of compliance systems, patient support programs, sales and marketing expenses and pre-commercial activities to support the commercial launch of MYQORZO in nHCM.

Cytokinetics' latest quarter

Questions

Did Cytokinetics raise or lower its guidance?

Cytokinetics (CYTK) raised its guidance on Nov 4, 2026: Stock-based compensation $130M–$140M for FY2026.

What does Cytokinetics expect?

We intend to leverage our experience in muscle contractility to expand our current pipeline and expect to identify additional potential drug candidates that may be suitable for clinical development and commercialization. Our market research supports our belief that MYQORZO will be highly competitive amongst cardiac myosin inhibitors, potentially eventually achieving a greater than 50% market share in the United States but also growing the cardiac myosin inhibitor category overall. At the same time, the National Institute for Health and Care Excellence (NICE) issued guidance recommending aficam

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.